BC-Monitor is a ctDNA-based liquid biopsy test that supports the molecular monitoring of breast cancer and the assessment of treatment response from a simple blood sample. In certain cases, these molecular changes may precede abnormalities detectable by conventional methods by several months 1
Our mission is to make tumor diagnostic tests that can be performed from blood or urine accessible to a wide range of people. Our mission is to create lasting value in the world by giving the very best of our knowledge, and to open up genetic diagnostics to broad segments of society.
1. Priskin K. et al., "BC-Monitor: Towards a Routinely Accessible Circulating Tumor DNA-Based Tool for Real-Time Monitoring Breast Cancer Progression and Treatment Effectiveness", Cancers (Basel), vol. 13, no. 14, p. 3489, Jul. 2021, doi: 10.3390/cancers13143489.
2. I. Grote, A. Poppe, U. Lehmann, M. Christgen, H. Kreipe, and S. Bartels, "Frequency of genetic alterations differs in advanced breast cancer between metastatic sites," Genes, Chromosomes and Cancer, vol. 63, no. 1, p. e23199, 2024, doi: 10.1002/gcc.23199.
3. J. O. Brett, L. M. Spring, A. Bardia, and S. A. Wander, "ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer", Breast Cancer Research, vol. 23, no. 1, p. 85, Aug. 2021, doi: 10.1186/s13058-021-01462-3.
Why is it important?
Early molecular insight can support timely decisions
During the treatment of breast cancer, it is essential to detect changes as early as possible. BC-Monitor can help identify changes in the status of the disease in a timely manner
Early indication
In certain cases, BC-Monitor may detect molecular signs of progression months before changes become apparent on imaging or tumor marker tests.1
Real-time monitoring
Serial monitoring of treatment response may help assess treatment effectiveness over time
Detection of resistance
It helps identify emerging drug resistance in time, supporting up-to-date therapeutic management
Monitoring tumor evolution
The genetic changes of the tumor can be monitored, supporting personalized treatment
Dr. Priskin
Katalin, PhD.
Scientific Director, molecular biologist
How the test is performed
A simple process, precise results
The BC-Monitor test provides a comprehensive view of the disease in four simple steps, using a single blood draw
Simple blood draw
The test begins with a routine blood draw, available through our contracted partners
Laboratory analysis
The sample is analyzed in our laboratory using advanced next-generation sequencing (NGS)
Detailed report
Our English-language report presents the clinical significance of the identified genetic alterations and their potential therapeutic implications, supported by scientific references
Medical consultation
The results are evaluated by the treating physician, who uses them to determine or, if necessary, modify the treatment plan
Liquid biopsy
The role of liquid biopsy in the patient journey
Liquid biopsy is based on the analysis of cell-free DNA fragments circulating in blood plasma, which in the case of cancer are partly tumor-derived (ctDNA), and whose quantity generally changes proportionally with tumor burden. These fragments enter the circulation actively or passively and represent the combined genetic profile of the primary tumor and metastases
Baseline status
Document the molecular baseline status before therapy begins
Clonal changes
Monitor clonal changes during treatment
Early detection
Progression or resistance may be detected at the molecular level before clinical symptoms appear
Objective monitoring
Objective monitoring of therapeutic response
BC-Monitor enables documentation of the baseline status before therapy begins, monitoring of the tested genetic alterations during treatment, and detection of progression or resistance at the molecular level, often before clinical, radiological or tumor marker-based signs become apparent 1
BC-Monitor has been specifically optimized for the follow-up of breast cancer. Its clinical suitability for monitoring breast cancer was validated in a prospective clinical study1
“Nagyon köszönöm közreműködését betegségem javulása érdekében, már felvettem a kapcsolatot a Margit Medical Centerrel, várom telefonhivásukat.Nagylelküségükért, fáradozásukért nem tudok elégszer köszönetet mondani. ”
S. Eszter
Budapest
European Life Technologies
About Us
European Life Technologies Hungary is at the forefront of cancer diagnostics development. As pioneers in liquid biopsy, we offer minimally invasive and easily accessible testing using advanced molecular technologies. This complements traditional diagnostic methods and supports the early detection of changes. Our proprietary platforms enable accurate tumor identification and monitoring, providing high precision in tumor profiling. We are not only shaping the field of liquid biopsy-based cancer diagnostics, but also building a professional community where those affected can share knowledge about the disease. Our goal is for European Life Technologies Hungary to become one of Europe's leading scientific center in liquid biopsy research and innovation. We aim to shape the future of personalized medicine so that people receive support in detecting, understanding and monitoring their disease as early as possible
FAQ
Frequently Asked Questions
We have collected the most common questions about BC-Monitor.
BC-Monitor does not replace imaging tests; it complements them. CT, MRI or PET scans show the size and location of the tumor. BC-Monitor, by contrast, monitors the molecular status of the tumor. It is important to emphasize that liquid biopsy can often detect tumor progression months earlier than conventional imaging procedures.
Contact
If you would like to discuss BC-Monitor in more detail, please complete this form and we will contact you.
BC-Monitor
European Life Technologies
BC-Monitor
European Life Technologies
BC-Monitor
European Life Technologies
BC-Monitor
European Life Technologies
BC-Monitor - Fájdalommentes emlőrák vizsgálatának új korszaka
